Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for diabetes, could interrupt this gut–brain disease pathway.
Introduction:
Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for diabetes, could interrupt this gut–brain disease pathway.
Why was this study needed?
Although DPP-4 inhibitors have shown neuroprotective signals in previous studies, the underlying mechanisms remain unclear. Understanding whether these drugs can modify gut inflammation, α-synuclein propagation, and gut microbiota could open new opportunities for drug repurposing in PD.
What did the study show?
Clinical Impact:
This study supports the concept of repurposing DPP-4 inhibitors as disease-modifying therapies for Parkinson's disease. By targeting gut inflammation, α-synuclein propagation, and microbiome dysbiosis, these agents may offer benefits beyond glucose control, although human clinical trials are needed.
Take-Home Message:
Sitagliptin attenuated gut inflammation, reduced α-synuclein spread from the gut to the brain, and improved neurological outcomes in a Parkinson's disease model. These findings highlight DPP-4 inhibitors as promising candidates for gut–brain axis–targeted therapy in Parkinson's disease.
Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...
Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...
Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...
Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...
Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...
Introduction: Antibiotic exposure is the best-established risk factor for Clostridioides difficile infection (CDI). However, the contribution of many commonly prescribed non-antibiotic medications has remained uncertain. This large Swedish population-based study evaluated the association between a...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.